DIALOG(R) File 351: DERWENT WPI

(c) 2000 DERWENT INFO LTD. All rts. reserv.

011971141

WPI Acc No: 98-388051/199833

Drugs containing peptide(s) with specific affines o phospholipid(s) such as phosphatidyl serine, for treatment of blood coagulation,

inflammatory and immunological disorders

Patent Assignee: MOCHIDA PHARM CO LTD (MOCH)

Inventor: HASEGAWA T; KURIYAMA S

Number of Countries: 021 Number of Patents: 001

Patent Family:

Patent No Kind Date Applicat No Kind Date Main IPC Week WO 9829453 A1 19980709 WO 98JP2 A 19980105 C07K-019/00 199833 B

Priority Applications (No Type Date): JP 96359053 A 19961227 Patent Details:

Patent Kind Lan Pg Filing Notes Application Patent

WO 9829453 A1 J 117

Designated States (National): CA JP KR US

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Abstract (Basic): WO 9829453 A

Drug compositions contain as active component a peptide which has specific affinity to particular phospholipids (such as phosphatidyl ethanolamine or phosphatidyl serine), especially to phospholipids which constitute a lipid bilayer of cellular cortex and of which the concentration in the bilayer increases in cells which are abnormal (e.g. through injury, denaturation or activation).

In particular, the peptide contains a sequence having phospholipid affinity and a structure of formula (I).

(A1)a-(A2)b-(A3)c (I)

- (A1) is one of two specific (130 and 30 amino acid) sequences given in the specification;
- (A2) and (A3) are TRYLRIHPQSWVHQIALR (II), LRYLRIHPQSWVHQIALR or MEVLGCEAQNLY (III);

a = 0-5;

b = 1-5, and

c = 0-5.

Preferred are the formulae A1-A2-A3, A2-A3, A2-A2-A3, A2-A2-A3 or A2-A2 (especially A2-A2-A3, A2-A2-A3 or A2-A2).

The sequence is linked to a peptide such as a blood factor, especially thrombo-modulin, urina-statin or membrane cofactor protein. Also claimed are:

- (1) peptides of sequence (I), and
- (2) DNAs encoding these peptides or encoding peptides with phospholipid affinity which incorporate them as part of the sequence.

USE - The drugs are used for the treatment and prevention of diseases involving blood coagulation, inflammatory and immunological disorders.

Dwg.0/22

Derwent Class: B04; D16

International Patent Class (Main): C07K-019/00

International Patent Class (Additional): A61K-047/48; C07K-014/745;

C12N-015/12; C12P-021/02; C12R-001-91